Hemab Therapeutics — Third Quarter 2026 Earnings Summary

Hemab Therapeutics initiated the SOLARA Phase 3 trial for sutacimig in Glanzmann thrombasthenia, marking the first pivotal study of a subcutaneous prophylactic treatment for the condition. The company also dosed its first participant in a Phase 1 trial for HMB-003 to treat heavy menstrual bleeding and reported early clinical data showing sutacimig significantly reduced prothrombin time in patients with Factor VII deficiency. Financially, the company reported a net loss of $27.3 million for the third quarter of 2026, with cash and marketable securities totaling $430.2 million to fund operations through 2029. Additionally, Hemab strengthened its Board of Directors by appointing Keli Walbert, who brings over two decades of commercial leadership experience in the biopharmaceutical industry.